Clinically,
rheumatoid arthritis (RA) is frequently accompanied by multi-system diseases. Among them, the incidence of comorbid
tumors in RA is relatively high, resulting in a gradual increase in mortality; this poses a considerable challenge to clinical treatment. To date, no effective treatment plan for simultaneous
tumor and RA
therapy is available. Accordingly, we reported a
sialic acid-modified
doxorubicin hydrochloride liposome (DOX-SAL) that targets peripheral blood neutrophils (PBNs), which play an important role in
tumors and RA. Furthermore, the prepared
liposome induced PBN apoptosis by binding to
L-selectin, which is highly expressed on the surface of PBNs activated by
inflammation. This
liposome, in turn, reduced the accumulation of inflammatory neutrophils at the disease site. In the first successfully established mouse model of RA comorbidity, induced by employing S180
sarcoma cells and
collagen, DOX-SAL effectively inhibited
tumor growth while simultaneously alleviating systemic RA symptoms without side effects. Additionally, the animals demonstrated adequate growth during the 48 days of treatment. This treatment strategy encompasses the best of both worlds, breaking the deadlock that
tumors and RA cannot be effectively treated in parallel, highlighting a new concept and reference for the clinical treatment of comorbid
tumors and RA.